Teladoc Health (NYSE: TDOC), the most high-profile stock in the rapidly emerging telehealth segment, closed almost 3.1% higher on Friday. There was no news of any note from the company that day; rather, its stock seems to be piggybacking on the successful debut of a peer telemedicine services provider.
That peer is Amwell (NYSE: AMWL), which made an auspicious debut in its first day of trading on Thursday and basically held its value the next day. Beset by intense demand, the new stock closed the day 28% higher than its initial public offering (IPO) price of $18. That price, meanwhile, was raised from Amwell's original $14 to $16 range.
Telemedicine as a segment is hot within the healthcare sector now. It's no mystery why -- the coronavirus pandemic has made people hesitant to leave their homes. Doctor's office waiting rooms, in which numerous people are frequently crowded together in a small space, are environments many are eager to avoid.
Meanwhile, the ever-relentless march of technology has improved to the point where anyone with even a basic smartphone, tablet, or PC can access telemedicine services.
Patients are discovering the advantages of remote medicine, so telehealth services providers should continue to thrive even after the pandemic (hopefully) fades away. Investors are justifiably excited about the prospects of the Amwells and Teladocs of the world, and admire their historical and potential revenue growth -- even if profitability is elusive for now.
10 stocks we like better than Teladoc Health
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 1, 2020
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.